IGFBP3
Insulin-like growth factor-binding protein 3
Also known as: BP-53, IBP3, IBP3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17936
- Gene
- IGFBP3
- Ensembl
- ENSG00000146674
- Chromosome
- 7
- Canonical length
- 291 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Vesicles
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
291 residues, UniProt reviewed canonical sequence.
>P17936|IGFBP3
1 MQRARPTLWA AALTLLVLLR GPPVARAGAS SAGLGPVVRC EPCDARALAQ CAPPPAVCAE
61 LVREPGCGCC LTCALSEGQP CGIYTERCGS GLRCQPSPDE ARPLQALLDG RGLCVNASAV
121 SRLRAYLLPA PPAPGNASES EEDRSAGSVE SPSVSSTHRV SDPKFHPLHS KIIIIKKGHA
181 KDSQRYKVDY ESQSTDTQNF SSESKRETEY GPCRREMEDT LNHLKFLNVL SPRGVHIPNC
241 DKKGFYKKKQ CRPSKGRKRG FCWCVDKYGQ PLPGYTTKGK EDVHCYSMQS KLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IGFBP3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.53
- Highest tissue expression
- 1,749 nTPM
Expression across tissuesHPA
Tissue
- placenta: 1,749 nTPM
- liver: 668 nTPM
- endometrium: 512 nTPM
- urinary bladder: 346 nTPM
- adipose tissue: 323 nTPM
- blood vessel: 289 nTPM
Single-cell type
- extravillous trophoblasts: 3,322 nCPM
- endometrial secretory cells: 816 nCPM
- hepatic stellate cells: 529 nCPM
- migrating cytotrophoblasts: 493 nCPM
- prostatic club cells: 458 nCPM
- basal keratinocytes: 385 nCPM
Immune cell
- plasmacytoid DC: 49 nTPM
- memory CD4 T-cell: 9.7 nTPM
- memory CD8 T-cell: 9.3 nTPM
- gdT-cell: 8.8 nTPM
- MAIT T-cell: 7.2 nTPM
- naive CD8 T-cell: 7.2 nTPM
Brain region
- hypothalamus: 24 nTPM
- basal ganglia: 21 nTPM
- pons: 21 nTPM
- choroid plexus: 19 nTPM
- medulla oblongata: 19 nTPM
- cerebral cortex: 16 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IGFBP3.
Disease | ImmuneIEDB
Conditions an epitope on IGFBP3 was assayed in.
- intrahepatic cholangiocarcinoma T cell
- bile duct adenocarcinoma T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.39
- gnomAD pLI
- 0.91
- gnomAD missense Z
- 0.79
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- MAPK cascade
- negative regulation of cell population proliferation
- negative regulation of protein phosphorylation
- negative regulation of signal transduction
- negative regulation of smooth muscle cell migration
- negative regulation of smooth muscle cell proliferation
- osteoblast differentiation
- positive regulation of apoptotic process
- positive regulation of insulin-like growth factor receptor signaling pathway
- positive regulation of MAPK cascade
- positive regulation of myoblast differentiation
- protein phosphorylation
- regulation of cell growth
- regulation of glucose metabolic process
- regulation of insulin-like growth factor receptor signaling pathway
- type B pancreatic cell proliferation
Molecular functions
- fibronectin binding
- insulin-like growth factor binding
- insulin-like growth factor I binding
- insulin-like growth factor II binding
- metal ion binding
- protein tyrosine phosphatase activator activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Thyroglobulin type-1
- Insulin-like growth factor-binding protein, IGFBP
- Growth factor receptor cysteine-rich domain superfamily
- Insulin-like growth factor binding protein, N-terminal, Cys-rich conserved site
- Insulin-like growth factor-binding protein family 1-6, chordata
- Thyroglobulin type-1 superfamily
- Thyroglobulin type-1 repeat
- Insulin-like growth factor binding protein
- Insulin-like growth factor binding protein 3
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IGFBP3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IGFBP3 as an antibody target. Whether an autoantibody or antibody against IGFBP3 could matter depends on whether native IGFBP3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IGFBP3 is annotated as secreted, so native IGFBP3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IGFBP3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...